Chemotherapy

F? February 2004, the USA Food and Drug Administration has approved? pemetrexed (brand name Alimta) for treatment of m? Soth? liom malignant pleural. Pemetrexed is administered? in combination with cisplatin. Folic acid is? Also used? r? reduce side-effects of pemetrexed

Immunotherapy
Treatments involving Immunother? Therapy have data? r? outcome variables. For example, intrapleural inoculation of Bacillus Calmette-Gu? Rin (BCG) in an attempt to stimulate the r? Immune response, a? T? jug? any e utilit? for the patient (while May benefit patients with bladder cancer). Mesothelioma proven? sensitive cells? in vitro lysis by LAK cells following activation of the interleukin-2 (IL-2), but the patients? that th? particularly therapy experienced major side effects. Indeed, this proc? S a? T? suspended because of unacceptable levels of IL-2, the Toxic? and burn? side effects such as fi? vre and cachexia. N? Nevertheless, other proc-s on the interf? Ron alpha av? R? More encouraging with 20% of patients experiencing more than 50% de r? Production of tumor associ? E? minimal side effects.

The chemotherapeutic? Therapy intrap? Riton? Ale perop? Laboratory heating
A trial lasts known as chemotherapeutic heating? Intrap therapy? Riton? Perop ale? A laboratory? T? d? developed? by Paul Sugarbaker e? Washington Cancer Institute [13]. The surgeon removes as much tumor as possible followed by the direct administration of a chemotherapeutic agent? Therapy, heating? E? between 40 and 48? C in the abdomen. The fluid is infused? for 60? 120 minutes, then? Drop?.
This technique allows? the administration of high concentrations of certain m? drugs in the abdomen and pelvis area. Heating of the chemotherapeutic? Therapy increases the rate of p? N? Tration of m? Drugs in tissues. Also, heating itself m? Me damage malignant cells more than normal cells.